IBD is associated with a young age at onset and normal life expectancy, which results in a lifetime accrual of disease-related costs. This Review discusses the economic impact of biologic therapy on direct costs of IBD, such as hospitalizations and surgeries, and indirect costs, such as those related to disability and loss of productivity.